Safety and efficacy of combination of vilanterol and Fluticasone furoate (once daily) in comparison to Salmetrol/fluticasone propionate (twice daily) in bronchial asthma

Abstract

The treatment of persistent asthma has been aided by the recent approval of new medications. Vilanterol (Ultra long-acting β2 Agonist) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/ vilanterol inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma and COPD; the combination of FF/VI at the dose of 100/25 μg daily improves trough peak expiratory flows and forced expiratory volume in 1s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma